Invivomab anti mouse cd4

Mice were depleted of CD4⁺ T cells with an intraperitoneal injection of 0.15 mg rat anti-mouse CD4 Ab clone GK1.5 (InVivoMAb anti-mouse CD4, BioXcell, West Lebanon, NH) or mock depleted with an intraperitoneal injection of 0.15mg anti-keyhole limpet hemocyanin (LTF, InVivoMAb rat IgG2b isotype control). Injections were given 2 days before infection, one day after infection and then every 6 days through 28 days post infection (dpi). The efficacy of CD4 depletion was confirmed by a lack of CD4⁺T cells in corneas of depleted mice as assessed by both confocal microscopy and flow cytometry (not shown).

For depletion of CD8/CD4 T Cells mice were injected intraperitoneally weekly with 250 µg InVivoMAb anti-mouse CD8α (BioXCell, BE0061), InVivoMAb anti-mouse CD4 (BioXcell, BE0003–1), or isotype control (BioXCell, BE0090) for a total of three times. For anti-PD-L1 mAb immunotherapy experiments, mice were injected intraperitoneally on day 5, 7, 9, and 12, with 100 µg InVivoMAb anti-mouse PD-L1 (BioXCell, BE0101) or InVivoMAb rat IgG2b isotype control (BioXCell, BE0090). For experiments in Fig. S4D mice were treated with daily Lr gavage (200µl, 10⁹ CFU) and received the first dose of 50 µg InVivoMAb anti-mouse PD-L1 (BioXCell, BE0101) or InVivoMAb rat IgG2b isotype control (BioXCell, BE0090) as indicated once tumors were established (~100 mm³). For Fig. S4E, mice were treated with daily Lr gavage (200µl, 10⁹ CFU) and received the first dose of 100µg InVivoMAb anti-mouse CTLA-4 (BioXCell, BE0164) or InVivoMAb mouse IgG2b isotype control (BioXCell, BE0086) as indicated once tumors were established (~100 mm³). For Fig. S8D, in conjunction with 100 µg InVivoMAb anti-mouse PD-L1 (BioXCell, BE0101) or InVivoMAb rat IgG2b isotype control (BioXCell, BE0090) treatment mice received 50 μL FICZ (200μg/mL) via intraperitoneal injection as indicated.